Outset Medical announced today that it received FDA 510(k) clearance for its next-generation Tablo hemodialysis platform.

The next-generation Tablo platform is expected to begin shipping to customers in the second quarter of 2026. Healthcare providers currently using Tablo will be eligible to upgrade to the new ...

Outset Medical plans to begin shipping the updated platform during the second quarter of 2026.

SAN JOSE, Calif.--(BUSINESS WIRE)-- Outset Medical, Inc. (Nasdaq: OM) (“Outset”) today announced that its Tablo® Hemodialysis System has received the first-ever approval from the Centers for Medicare ...

Outset Medical stock jumps after FDA clears next-gen Tablo dialysis system, the first to meet the agency's latest ...

SAN JOSE, Calif.--(BUSINESS WIRE)--Fifty-seven year old dialysis patient Tracey Amadi of central New Jersey is the first person in the world to use Outset Medical’s mobile Tablo Hemodialysis System at ...

Please provide your email address to receive an email when new articles are posted on . ORLANDO — In this video from ASN Kidney Week, Michael Aragon, MD, the chief medical officer of Outset Medical, ...

Guam to receive HHS emergency deployment of Outset Medical’s mobile, easy-to-use dialysis technology for patients with kidney failure. “Tablo’s ease of use enables health care professionals, even ...

Outset Medical continued to face a multivariate equation of headwinds last quarter. The stock has continued its long-term downtrend whilst technical indicators aren't signalling a reversal any time ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — Data presented at ASN Kidney Week show Outset Medical’s Tablo hemodialysis system was safe and ...